SMZL specific biomarkers

Diagnose, monitor rare lymphoma with blood sample


  • Novel biomarkers for splenic marginal zone lymphoma
  • Positively diagnose SMZL from all other B-cell lymphomas
  • Measure biomarkers in blood and in fresh or preserved splenic biopsies
  • Potential to monitor SMZL progression in real-time
    Licensing Manager: Tyler Scherr, Ph.D. or 402-559-2140


Diagnose, monitor rare lymphoma with blood sample

A new set of biomarkers could help in the diagnosis and prognosis of a rare form of cancer.
Splenic marginal zone lymphoma, a cancer of the spleen, affects approximately 2,000 people annually in the United States. However, current diagnosis is often times unclear and typically requires removal of part or all of the spleen.
By systematically analyzing 39,000 genes present in 437 clinical samples across 13 clinical datasets, researchers at the University of Nebraska at Omaha identified a unique 135-gene profile unique to this rare form of splenic lymphoma. Intriguingly, separate subsets of seven and two biomarkers were demonstrated to be greater than 93 percent accurate at diagnosing splenic lymphoma versus all other B-cell lymphomas.
Unlike most diagnostics, these biomarkers can be measured in blood as well as fresh or preserved tissue samples.
With further validation, these biomarkers could also be used to monitor splenic lymphoma progression and metastasis in real-time, enabling oncologists to provide timely and effective treatment.
Contact Tyler Scherr, Ph.D., at or 402-559-2140 to discuss licensing opportunities.

Additional Information


News Reports